Real-world long-term outcomes of advanced/metastatic NSCLC patients treated with EGFR TKIs in Nottinghamshire

被引：0
|
作者：
Lopez-Escola, C. [1 ]
Mengoli, K. [1 ]
Sheikh, O. [1 ]
Karim, S. [1 ]
Sadiq, M. [1 ]
机构：
[1] Nottingham Univ Hosp NHS Trust, Nottingham, England
来源：
LUNG CANCER | 2020年 / 139卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
140
引用
收藏
页码：S62 / S62
页数：1
相关论文
共 50 条
  • [1] Long-term survival of NSCLC patients with EGFR mutations treated with EGFR TKIs gefitinib or erlotinib
    Janne, R
    Sequist, L
    Lindeman, N
    Bell, D
    Huberman, M
    Meyerson, M
    Haber, D
    Lynch, T
    Johnson, B
    [J]. LUNG CANCER, 2005, 49 : S109 - S109
  • [2] A Real-World Cohort Study of EGFR TKIs in Patients with NSCLC with Uncommon EGFR mutations (UpSwinG)
    Miura, S.
    Hsia, T.
    Hung, J.
    Jung, H. A.
    Shih, J.
    Park, C.
    Lee, S. H.
    Okamoto, T.
    Ahn, H. K.
    Lee, Y. C.
    Sato, Y.
    Lee, S. S.
    Mascaux, C.
    Daoud, H.
    Maerten, A.
    Popat, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1115 - S1116
  • [3] REAL-WORLD LONG TERM OUTCOMES IN NATALIZUMAB TREATED PATIENTS
    Wynford-Thomas, Ray
    Owen, Helen
    Mulloch, Sue
    Evans, Peter
    Conway, Bernie
    Watson, Lynne
    Pearson, Owen
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2016, 87 (12):
  • [4] EGFR TKIs in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG)
    Miura, S.
    Hsia, T-C.
    Hung, J-Y.
    Jung, H. A.
    Shih, J-Y.
    Park, C-K.
    Lee, S. H.
    Okamoto, T.
    Ahn, H. K.
    Lee, Y. C.
    Sato, Y.
    Lee, S. S.
    Mascaux, C.
    Daoud, H.
    Maerten, A.
    Popat, S.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S967 - S968
  • [5] Long-term survival of real-world advanced melanoma patients treated with targeted therapy
    Ismail, R.
    de Boer, A.
    van Dartel, M.
    Hilarius, D.
    van Zeijl, M.
    van den Eertwegh, F.
    Aarts, M.
    Van den Berkmortel, F.
    Boers-Sonderen, M.
    de Groot, J. W. B.
    Haanen, J. B. A. G.
    Hospers, G. A. P.
    Kapiteijn, E.
    Piersma, D.
    van Rijn, R.
    Suijkerbuijk, K. P. M.
    ten Tije, A. J.
    Van der Veldt, A. A. M.
    Vreugdenhil, G.
    Wouters, M.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S745 - S746
  • [6] Real-World Treatment Patterns and Clinical Outcomes in Advanced/Metastatic NSCLC Patients in England
    Verleger, Katharina
    Hertel, Nadine
    Solem, Caitlyn
    Penrod, John R.
    Macahilig, Cynthia
    Luo, Linlin
    Crawford, S. Michael
    [J]. BRITISH JOURNAL OF CANCER, 2018, 119 (11) : 5 - 5
  • [7] Real-World Characteristics and Outcomes of Advanced NSCLC Patients with Exon 19 or 21 EGFR Mutations
    Winfree, K.
    Molife, C.
    Peterson, P.
    Chen, Y.
    Visseren, C.
    Beyrer, J.
    Leusch, M.
    Dimou, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S23 - S23
  • [8] Real-World Outcomes of Advanced NSCLC Patients with Common and Uncommon/Complex EGFR Mutation Profiles
    Riely, G.
    Lovly, C.
    Messina, C.
    Bienert, S.
    Alexander, K.
    Pao, W.
    Magee, K.
    Baxi, S.
    Doebele, R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S365 - S366
  • [9] Real-World Data of Osimertinib in Patients with Metastatic EGFRm plus NSCLC who Progressed on First-Line EGFR TKIs
    Ma, J.
    Tan, S. H.
    Yin, D.
    Tran, A.
    Tan, D.
    Ang, M.
    Takano, A.
    Lim, K. H. T.
    Kanesvaran, R.
    Jain, A.
    Rajasekaran, T.
    Tan, E.
    Lim, D. W.
    Ng, Q. S.
    Tan, W.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S627 - S628
  • [10] The Effect of Metformin on Survival Outcomes of Advanced EGFR-mutant NSCLC Patients Treated with EGFR TKIs in Thailand
    Saichaemchan, S.
    Kanjanavithayakul, Y.
    Prasongsook, N.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S484 - S485
12345